No question in medicines information punishes oversimplification like pregnancy. "Is it safe?" has no honest one-word answer, because the real answer depends on gestational stage, dose and duration, the maternal indication and the risks of leaving it untreated, the route, the alternatives available, and the strength of an evidence base that is, for structural reasons, almost never trial-grade. The UK stack for this question is genuinely good, better than most clinicians realise, and the skill is knowing which source carries which piece. Here is the map, and how to run the conversation from it.
The resource stack
The BNF gives the concise clinical interpretation per drug, the fast professional orientation. The exact product's SmPC section 4.6 gives the authorised wording on fertility, pregnancy and lactation, licence-anchored and often conservative, for reasons worth understanding rather than resenting. UKTIS, the UK Teratology Information Service, is the professional layer: evidence-based teratology information on exposure in pregnancy, supplying scientific assessments that inform bodies including the MHRA and the BNF itself. BUMPS, Best Use of Medicines in Pregnancy, is UKTIS's patient-facing sibling: leaflets based on the same scientific material, written for the person actually pregnant. SPS covers defined pregnancy and breastfeeding practicalities. Local obstetric and specialty guidance carries the pathway. And iatroX Medicines provides the rapid per-medicine summary with the pregnancy sources linked, the orientation step before the deeper layers.
Patient-facing versus professional information
The stack's most useful property is that it separates audiences on purpose, and using it well means respecting the separation. BUMPS is written for patients; UKTIS for professionals; the SmPC for neither exactly, it is a regulatory text, and sending an anxious patient into section 4.6 unaccompanied is how routine reassurance becomes a crisis. The working pattern: the clinician reads UKTIS and the BNF, understands the shape of the evidence, then shares the BUMPS leaflet as the take-home, and the conversation is shared decision-making rather than reassurance-by-sentence, because the honest content is usually "here is what the evidence shows, here is what untreated illness risks, here is what we recommend and why".
Why the SmPC often sounds more cautious
A pattern worth pre-explaining to patients who will read the leaflet anyway: authorised product wording is bound to the evidence submitted for the licence, and pregnant women are systematically excluded from trials, so the regulatory text frequently defaults to caution that specialist assessment of accumulated real-world evidence has since superseded. When the SmPC and UKTIS diverge in tone, both are doing their jobs; the professional synthesis is the clinician's, documented.
Worked examples
Amoxicillin: the commonest shape of the question, a first-line antibiotic with reassuring accumulated experience, where the page's linked NHS and pregnancy sources support a short, confident conversation, and the indication itself does most of the deciding. Nitrofurantoin: the stage-dependent shape, where gestational timing, renal function, the indication and product-specific warnings interact, and the answer at one point in pregnancy is not the answer at another; the clinical page's framing plus UKTIS carries it. Apixaban: the specialist-review shape, anticoagulation in pregnancy is a pathway decision about alternatives, not a leaflet decision, and the stack's job is to route fast to the specialist layer. Paracetamol: the self-care shape, a common question deserving context about indication and sensible use rather than a bare yes, with the patient-facing sources doing the explaining.
Frequently asked questions
Is BUMPS reliable?
Yes: its leaflets are based on scientific material prepared by UKTIS, incorporating the published evidence, which makes it the rare patient-facing source with a professional evidence engine underneath.
What is the difference between BUMPS and UKTIS?
Audience and depth: same evidence base, with UKTIS serving professionals, and its information feeding national bodies, and BUMPS translating it for patients.
What should be documented after the conversation?
The exposure or proposed treatment, the sources consulted, the risks discussed in both directions, treated and untreated, the decision and its rationale, and the follow-up plan. The documentation is the shared decision made durable.
Where do breastfeeding questions fit?
Same stack, adjacent sources: the SmPC's 4.6, SPS's breastfeeding guidance, and the specialist services; the pregnancy discipline, evidence over labels, transfers wholesale.
Should medicines be stopped pre-emptively when pregnancy is confirmed?
Not reflexively: abrupt discontinuation of necessary treatment is itself a risk, and the correct move is prompt review, with the stack above, of each medicine's evidence against the risks of the untreated condition. "Stop everything" is the error the professional layer exists to prevent, in both directions.
Who do professionals contact for complex cases?
UKTIS's professional service for teratology questions, the relevant specialist team for pathway decisions, and pharmacy for the practical residue; the routing matters more than heroic solo synthesis.